Kasinger James R. (CIK 0001708172)

Latest company ownership

Role: General Counsel and Secretary
Shares held
2,114
Last filed at
Oct 15, 2025
Confidence Score
44.1
2025Q4
Confidence Score History
2021Q1 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Oct 13, 2025 Oct 15, 2025 CRISPR Therapeutics AG General Counsel and Secretary Sell 42.5 -1,076 -1.27% $71.7K
Mar 20, 2025 Mar 24, 2025 CRISPR Therapeutics AG General Counsel and Secretary Sell 42.5 -3,185 -3.75% $131.3K
Mar 10, 2025 Mar 12, 2025 CRISPR Therapeutics AG General Counsel and Secretary Sell 42.5 -3,966 -2.48% $169.2K
Feb 16, 2025 Feb 19, 2025 CRISPR Therapeutics AG General Counsel and Secretary Sell 40.0 -11,542 -7.24% $619.5K
Oct 13, 2024 Oct 15, 2024 CRISPR Therapeutics AG General Counsel and Secretary Sell 42.5 -1,089 -1.71% $50.4K
Mar 10, 2024 Mar 12, 2024 CRISPR Therapeutics AG General Counsel and Secretary Sell 40.0 -3,947 -3.15% $304.5K
Feb 18, 2024 Feb 21, 2024 CRISPR Therapeutics AG General Counsel and Secretary Sell 42.5 -1,913 -3.23% $152.4K
Mar 10, 2023 Mar 14, 2023 CRISPR Therapeutics AG General Counsel and Secretary Sell 42.5 -2,305 -2.08% $99.6K
Feb 18, 2023 Feb 22, 2023 CRISPR Therapeutics AG General Counsel and Secretary Sell 42.5 -1,950 -3.61% $94.1K
Dec 3, 2022 Dec 6, 2022 CRISPR Therapeutics AG General Counsel and Secretary Sell 42.5 -3,234 -6.05% $169K
Mar 10, 2022 Mar 14, 2022 CRISPR Therapeutics AG General Counsel and Secretary Sell 42.5 -2,360 -2.51% $146.1K
Dec 3, 2021 Dec 7, 2021 CRISPR Therapeutics AG General Counsel and Secretary Sell 40.0 -6,303 -12.65% $436K
Sep 10, 2021 Sep 14, 2021 CRISPR Therapeutics AG General Counsel and Secretary Sell 40.0 -4,741 -13.98% $558.8K
Mar 10, 2021 Mar 12, 2021 CRISPR Therapeutics AG General Counsel and Secretary Sell 42.5 -1,353 -5.36% $168K
Jan 19, 2021 Jan 20, 2021 CRISPR Therapeutics AG General Counsel and Secretary Sell 3.8 -27,500 -55.08% $5.6M